Global Geographic Atrophy 麻豆原创 Research Report 2023

Publication ID:

PB511233292

Publication Date:

November 2, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that causes a continuous progressive degeneration of the macula. The condition is characterized by widespread atrophy of the outer retinal tissue, retinal pigment epithelium, and choriocapillaris. It typically starts in the perifoveal region and develops to the fovea over time and causing central scotomas and permanent vision loss. Various drugs and treatments are under evaluation.
The global Geographic Atrophy market is projected to reach US$ 1714 million in 2029, increasing from US$ 1123 million in 2022, with the CAGR of 6.3% during the period of 2023 to 2029.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents鈥� wealth and the improvement of health awareness will drive the demand for medicines.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Geographic Atrophy market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Apellis Pharmaceuticals
Iveric Bio
Alkeus Pharmaceuticals
Hemera Biosciences
Allegro Ophthalmics
Stealth BioTherapeutics
Gyroscope Therapeutics
Regenerative Patch Technologies
Roche
Gensight Biologics
NGM Biopharmaceuticals
AstraZeneca
Lineage Cell Therapeutics
Allergan
Segment by Type
Above 60 Years
Above 75 Years
Segment by Application
Late-stage (Phase III)
Phase II
Phase I
Pre-clinical stage
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Geographic Atrophy report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Geographic Atrophy 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Above 60 Years
1.2.3 Above 75 Years
1.3 麻豆原创 by Application
1.3.1 Global Geographic Atrophy 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Late-stage (Phase III)
1.3.3 Phase II
1.3.4 Phase I
1.3.5 Pre-clinical stage
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Geographic Atrophy 麻豆原创 Perspective (2018-2029)
2.2 Geographic Atrophy Growth Trends by Region
2.2.1 Global Geographic Atrophy 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Geographic Atrophy Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Geographic Atrophy Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Geographic Atrophy 麻豆原创 Dynamics
2.3.1 Geographic Atrophy Industry Trends
2.3.2 Geographic Atrophy 麻豆原创 Drivers
2.3.3 Geographic Atrophy 麻豆原创 Challenges
2.3.4 Geographic Atrophy 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Geographic Atrophy Players by Revenue
3.1.1 Global Top Geographic Atrophy Players by Revenue (2018-2023)
3.1.2 Global Geographic Atrophy Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Geographic Atrophy 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Geographic Atrophy Revenue
3.4 Global Geographic Atrophy 麻豆原创 Concentration Ratio
3.4.1 Global Geographic Atrophy 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Geographic Atrophy Revenue in 2022
3.5 Geographic Atrophy Key Players Head office and Area Served
3.6 Key Players Geographic Atrophy Product Solution and Service
3.7 Date of Enter into Geographic Atrophy 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Geographic Atrophy Breakdown Data by Type
4.1 Global Geographic Atrophy Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Geographic Atrophy Forecasted 麻豆原创 Size by Type (2024-2029)
5 Geographic Atrophy Breakdown Data by Application
5.1 Global Geographic Atrophy Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Geographic Atrophy Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Geographic Atrophy 麻豆原创 Size (2018-2029)
6.2 North America Geographic Atrophy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Geographic Atrophy 麻豆原创 Size by Country (2018-2023)
6.4 North America Geographic Atrophy 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Geographic Atrophy 麻豆原创 Size (2018-2029)
7.2 Europe Geographic Atrophy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Geographic Atrophy 麻豆原创 Size by Country (2018-2023)
7.4 Europe Geographic Atrophy 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Geographic Atrophy 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Geographic Atrophy 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Geographic Atrophy 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Geographic Atrophy 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Geographic Atrophy 麻豆原创 Size (2018-2029)
9.2 Latin America Geographic Atrophy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Geographic Atrophy 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Geographic Atrophy 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Geographic Atrophy 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Geographic Atrophy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Geographic Atrophy 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Geographic Atrophy 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Apellis Pharmaceuticals
11.1.1 Apellis Pharmaceuticals Company Detail
11.1.2 Apellis Pharmaceuticals Business Overview
11.1.3 Apellis Pharmaceuticals Geographic Atrophy Introduction
11.1.4 Apellis Pharmaceuticals Revenue in Geographic Atrophy Business (2018-2023)
11.1.5 Apellis Pharmaceuticals Recent Development
11.2 Iveric Bio
11.2.1 Iveric Bio Company Detail
11.2.2 Iveric Bio Business Overview
11.2.3 Iveric Bio Geographic Atrophy Introduction
11.2.4 Iveric Bio Revenue in Geographic Atrophy Business (2018-2023)
11.2.5 Iveric Bio Recent Development
11.3 Alkeus Pharmaceuticals
11.3.1 Alkeus Pharmaceuticals Company Detail
11.3.2 Alkeus Pharmaceuticals Business Overview
11.3.3 Alkeus Pharmaceuticals Geographic Atrophy Introduction
11.3.4 Alkeus Pharmaceuticals Revenue in Geographic Atrophy Business (2018-2023)
11.3.5 Alkeus Pharmaceuticals Recent Development
11.4 Hemera Biosciences
11.4.1 Hemera Biosciences Company Detail
11.4.2 Hemera Biosciences Business Overview
11.4.3 Hemera Biosciences Geographic Atrophy Introduction
11.4.4 Hemera Biosciences Revenue in Geographic Atrophy Business (2018-2023)
11.4.5 Hemera Biosciences Recent Development
11.5 Allegro Ophthalmics
11.5.1 Allegro Ophthalmics Company Detail
11.5.2 Allegro Ophthalmics Business Overview
11.5.3 Allegro Ophthalmics Geographic Atrophy Introduction
11.5.4 Allegro Ophthalmics Revenue in Geographic Atrophy Business (2018-2023)
11.5.5 Allegro Ophthalmics Recent Development
11.6 Stealth BioTherapeutics
11.6.1 Stealth BioTherapeutics Company Detail
11.6.2 Stealth BioTherapeutics Business Overview
11.6.3 Stealth BioTherapeutics Geographic Atrophy Introduction
11.6.4 Stealth BioTherapeutics Revenue in Geographic Atrophy Business (2018-2023)
11.6.5 Stealth BioTherapeutics Recent Development
11.7 Gyroscope Therapeutics
11.7.1 Gyroscope Therapeutics Company Detail
11.7.2 Gyroscope Therapeutics Business Overview
11.7.3 Gyroscope Therapeutics Geographic Atrophy Introduction
11.7.4 Gyroscope Therapeutics Revenue in Geographic Atrophy Business (2018-2023)
11.7.5 Gyroscope Therapeutics Recent Development
11.8 Regenerative Patch Technologies
11.8.1 Regenerative Patch Technologies Company Detail
11.8.2 Regenerative Patch Technologies Business Overview
11.8.3 Regenerative Patch Technologies Geographic Atrophy Introduction
11.8.4 Regenerative Patch Technologies Revenue in Geographic Atrophy Business (2018-2023)
11.8.5 Regenerative Patch Technologies Recent Development
11.9 Roche
11.9.1 Roche Company Detail
11.9.2 Roche Business Overview
11.9.3 Roche Geographic Atrophy Introduction
11.9.4 Roche Revenue in Geographic Atrophy Business (2018-2023)
11.9.5 Roche Recent Development
11.10 Gensight Biologics
11.10.1 Gensight Biologics Company Detail
11.10.2 Gensight Biologics Business Overview
11.10.3 Gensight Biologics Geographic Atrophy Introduction
11.10.4 Gensight Biologics Revenue in Geographic Atrophy Business (2018-2023)
11.10.5 Gensight Biologics Recent Development
11.11 NGM Biopharmaceuticals
11.11.1 NGM Biopharmaceuticals Company Detail
11.11.2 NGM Biopharmaceuticals Business Overview
11.11.3 NGM Biopharmaceuticals Geographic Atrophy Introduction
11.11.4 NGM Biopharmaceuticals Revenue in Geographic Atrophy Business (2018-2023)
11.11.5 NGM Biopharmaceuticals Recent Development
11.12 AstraZeneca
11.12.1 AstraZeneca Company Detail
11.12.2 AstraZeneca Business Overview
11.12.3 AstraZeneca Geographic Atrophy Introduction
11.12.4 AstraZeneca Revenue in Geographic Atrophy Business (2018-2023)
11.12.5 AstraZeneca Recent Development
11.13 Lineage Cell Therapeutics
11.13.1 Lineage Cell Therapeutics Company Detail
11.13.2 Lineage Cell Therapeutics Business Overview
11.13.3 Lineage Cell Therapeutics Geographic Atrophy Introduction
11.13.4 Lineage Cell Therapeutics Revenue in Geographic Atrophy Business (2018-2023)
11.13.5 Lineage Cell Therapeutics Recent Development
11.14 Allergan
11.14.1 Allergan Company Detail
11.14.2 Allergan Business Overview
11.14.3 Allergan Geographic Atrophy Introduction
11.14.4 Allergan Revenue in Geographic Atrophy Business (2018-2023)
11.14.5 Allergan Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Apellis Pharmaceuticals
Iveric Bio
Alkeus Pharmaceuticals
Hemera Biosciences
Allegro Ophthalmics
Stealth BioTherapeutics
Gyroscope Therapeutics
Regenerative Patch Technologies
Roche
Gensight Biologics
NGM Biopharmaceuticals
AstraZeneca
Lineage Cell Therapeutics
Allergan

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.